Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
1
Date of announcement
2022/03/23
Time of announcement
14:11:35
Subject
CCSB is invited to attend the Investor Conference held by
Fubon Securities.
Date of events
2022/03/24
To which item it meets
paragraph 12
Statement
1.Date of institutional investor conference:2022/03/24
2.Time of institutional investor conference:14:00
3.Location of institutional investor conference:
Online investor conference
4.Outline of institutional investor conference:
CCSB's financial result of 2021 and the company future operational
strategy.
5.Any other matters that need to be specified:
Contact for registration：fion.hsieh@fubon.com
Please refer to MOPS website for complete financial and business
information.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 23 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 March 2022 06:23:05 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. 
